Researchers used imiquimod to reduce angiotensin‐converting enzyme 2(ACE2) and increase IFN‐β expression to trigger viral resistance mechanisms in human bronchial epithelial cells and subsequently improve viral infection tolerance by reducing the levels of epithelial cytokines induced by viral stimulation involved in severe COVID‐19 infection.326. Here, ACE2 is linked to viral infectious disease.